Nutriband Sells 90% Pocono Stake for $5M, Proceeds Fund AVERSA Fentanyl
Nutriband agreed to sell 90% interest in its Pocono Pharmaceutical subsidiary to EarthVision Bio for $5M, retaining a 10% stake with closing expected Dec. 31, 2025. The company will deploy proceeds to advance AVERSA Fentanyl development, and shares rose 16% on the announcement.
1. Strategic Divestiture Strengthens Balance Sheet
In December 2025, Nutriband Inc. completed the sale of 90% of its Pocono subsidiary to EarthVision Bio for $5 million in cash, a transaction that adds directly to the company’s bottom line without any dilution to common shareholders. Nutriband retains a 10% equity interest in the new entity, preserving upside participation if the subsidiary pursues a listing on a major U.S. exchange. Management emphasized that the proceeds will be redeployed into core operations, particularly to accelerate late-stage development and commercialization activities for its lead product candidate.
2. Preferred Stock Dividend Rewards Shareholders
In July 2025, Nutriband declared a 25% preferred stock dividend, issuing one preferred share for every four shares of common stock held as of the July 25 record date, with distribution completed on August 5. Each preferred share is convertible into one common share upon FDA approval of the AVERSA™ Fentanyl patch. Unconverted preferred shares will carry an annual cash dividend, subject to board approval, aligning income potential with the company’s profitability and reinforcing management’s commitment to shareholder returns.
3. AVERSA™ Fentanyl Advances Toward Commercial Launch
During 2025, Nutriband achieved multiple regulatory and manufacturing milestones for AVERSA™ Fentanyl, the world’s first abuse-deterrent transdermal fentanyl patch. In February, the U.S. Patent Office issued a Notice of Allowance for the core transdermal abuse-deterrent patent, and the company signed an addendum with Kindeva Drug Delivery to formalize exclusive development and cost-sharing arrangements. By June, patent number 12,318,492 was granted for misuse deterrent systems, and commercial scale-up of the manufacturing process was completed. In August, the FDA granted a Type C Meeting to review CMC plans from IND submission through a 505(b)(2) NDA, setting the stage for pivotal discussions ahead of a potential approval pathway.
4. Index Inclusions and Warrant Expiration as Potential Catalysts
Nutriband was added to four Russell indexes—Microcap, Microcap Growth, 3000E and 3000E Growth—during the July 2025 reconstitution, broadening the company’s visibility among institutional investors. Additionally, management highlighted the October 2026 expiration of outstanding IPO warrants as a potential catalyst for reduced share overhang and lower volatility, underscoring the importance of this event as the company approaches key commercialization inflection points.